Latest news with #GiovanniDiNapoli
Yahoo
16-07-2025
- Business
- Yahoo
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge
Dublin, Ireland--(Newsfile Corp. - July 16, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in its sustainability journey, underscoring its ambition to lead the next decade of healthcare innovation with purpose, transparency, and impact. In the past year, Cosmo has taken bold steps to embed ESG into the core of its business. This has been delivering measurable results that now place the Company among the top sustainability performers in its industry: MSCI ESG Rating Upgraded to 'A' – Cosmo has advanced from 'BBB' to 'A', placing it ahead of many mid-cap peers globally. The upgrade recognizes Cosmo's tangible progress on carbon emissions, workforce engagement, and board-level governance. LSEG ESG Score Doubled – Now Ranked #42 Globally in the peer group. With its score rising from 31.31 to 62.98, Cosmo has broken into the top 100 for the first time, signalling growing investor confidence and ESG credibility. Signatory to the United Nations Global Compact – Cosmo has joined the world's largest corporate sustainability initiative, aligning its strategy with the UN's Ten Principles on human rights, labour, environment, and anti-corruption. Formal Commitment to the Science Based Targets initiative (SBTi) – In a decisive move toward climate accountability, Cosmo has pledged to set science-based emissions reduction targets in line with the Paris Agreement. Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented: 'Cosmo is evolving into a new kind of healthcare company, where scientific innovation, operational excellence, and environmental stewardship are inseparable. These milestones are not checkboxes; they are foundational to our long-range ambition. ESG is not a side initiative – it is core to building a high-performance, future-ready business. We're proud of the progress, and even more determined to lead with discipline, transparency, and speed.' Niall Donnelly, EVP Corporate Governance and Chief Sustainability Officer, added: 'These upgrades reflect years of internal work to make ESG part of how we think, decide, and operate. The journey doesn't end here. Our SBTi commitment and UN Compact engagement show we are not just signalling intent. We are taking action that is measurable, science-aligned, and investor-relevant.' These achievements build on Cosmo's Vision 2030 strategy, which places ESG at the intersection of innovation and execution. As sustainability becomes a defining metric for healthcare investors, Cosmo is positioned to capture growing capital inflows from Article 8 and Article 9 SFDR-aligned funds and other ESG-driven portfolios. The Company's latest ESG Report, performance metrics, and future goals can be accessed at: About Cosmo Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit Financial calendar Half-Year 2025 Results and Report H.C. Wainwright 27th Annual Global Investment Conference, New York City, USA Jefferies Global Healthcare Conference, London, United Kingdom ODDO BHF Forum, Lyon, France July 23, 2025 September 8-10, 2025 November 17-20, 2025 January 8-9, 2026 For further information, please contact: Attachments PDF - English To view the source version of this press release, please visit
Yahoo
25-06-2025
- Business
- Yahoo
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell 'Digital Trust' to its existing customer Tinexta InfoCert, Europe's largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo. 'Digital Trust' provides services within the digital security sector, offering IT solutions for digital identity protection and process dematerialization for healthcare organizations. The decision to sell 'Digital Trust' is part of a broader effort to streamline the Company's portfolio and reinforce its position as a focused, performance-driven organization. Cosmo is executing a clear strategic direction – prioritizing growth in AI-powered medical devices, gastrointestinal therapeutics, dermatology, and high-value CDMO services – while actively reallocating capital to the areas with the highest impact. 'Digital Trust is not a strategic asset for Cosmo, and this transaction reflects our disciplined focus on what drives the greatest impact for patients and shareholders,' said Giovanni Di Napoli, CEO of Cosmo. 'This is another concrete step forward in positioning Cosmo for sustainable growth by strengthening our focus on innovation and operational excellence in our core markets.' Cosmo continues to execute its strategy to build a focused, innovation-driven healthcare company with global reach, leveraging its strong capabilities in R&D, AI integration, and commercial partnerships. About Cosmo Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people's lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit Financial calendar Investor Day, Zurich July 1, 2025 2025 Half-Year Results and Report July 23, 2025 For further information, please contact: Cosmo Pharmaceuticals Investor Relations, About Tinexta InfoCert Tinexta Infocert, part of the Tinexta Group, is the largest Certification Authority in Europe, operating in over 20 countries. The Company provides services in digitalization, eDelivery, Digital Signature, and digital document preservation. It is an AgID-accredited operator of digital identity within the framework of SPID (Public System for the Management of Digital Identity). It aims to continue expanding internationally also through acquisitions: it holds 100% of CertEurope, the largest Certification Authority in France; 51% of Camerfirma, one of the main certification authorities in Spain; and 16.7% of Authada, an innovative German Identity Provider. DisclaimerSome of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. Attachments PDF - English To view the source version of this press release, please visit Sign in to access your portfolio
